{"entity":{"id":"qurient","kind":"company","name":"Qurient","aka":["Qurient Co., Ltd.","Qurient Co Ltd"],"tldr":"Qurient is a South Korean biotechnology company in Seongnam that leads two cancer trials in OnCo, testing the selective CDK7 inhibitor Q901 and the Axl/Mer/CSF1R inhibitor Q702, each with pembrolizumab, in advanced solid tumours.","summary":"Qurient is a company based in Seongnam, South Korea (Wikidata Q30253835; no website is recorded there, so none is given here). ClinicalTrials.gov classes it as an industry sponsor, with Merck Sharp & Dohme as collaborator on the pembrolizumab combinations. It leads two phase 1/2 trials recorded in OnCo: NCT05394103 (Q901, a highly selective CDK7 inhibitor, alone and with pembrolizumab in selected advanced solid tumours) and NCT05438420 (Q702, an oral Axl/Mer/CSF1R tyrosine kinase inhibitor, with pembrolizumab, recorded under cervical cancer). Both compounds are its own, the basis for the biotech type.","asOf":"2026-09-22","links":[{"label":"Wikidata Q30253835","url":"https://www.wikidata.org/wiki/Q30253835"},{"label":"ClinicalTrials.gov: trials led by Qurient Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Qurient%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor","wave5-sponsor"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["axl","csf1r"],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05394103","nct05438420"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo content wave 5 (Wikidata, ClinicalTrials.gov v2, corpus trial records)","editedOn":"2026-09-22"},"hq":"Seongnam","country":"KR","companyType":"biotech","investors":[],"funding":[]},"route":"/companies/qurient/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/"},{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"nct05394103","kind":"trial","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","route":"/trials/nct05394103/"},{"id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/"}]}}